Sionna Therapeutics
Tracked across 2 events · 12 articles · First seen Aug 10, 2026 · Last active Aug 17, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Sionna Therapeutics reported that its Phase 2a PreciSION CF trial of SION-719 failed to achieve its key activity endpoint for sweat chloride reduction, with a placebo-adjusted change of -1.0 mmol/L (p=0.7) when added to standard…
Impact: Sionna Therapeutics is the central entity; its lead candidate SION-719 failed a Phase 2a trial, causing a ~90% stock drop and triggering a securities investigation. The company's future prospects are severely diminished.
Aug 12, 2026 · 6 articles
Business
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company developing oral therapies for neurologic diseases, announced the appointment of Elena Ridloff, CFA, to its Board of Directors, effective August 6, 2026. Ridloff brings over two decades…
Impact: Sionna Therapeutics is mentioned as Ridloff's current employer, but is not directly affected by this event.
Aug 10, 2026 · 6 articles
100
Sionna Therapeutics reported failed trialSionna Therapeutics...
100
Sionna Therapeutics lost 90% market valueSionna Therapeutics...
80
Levi & Korsinsky launched investigation Sionna TherapeuticsSionna Therapeutics...
ERGEN INTELLIGENCE
Track Sionna Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard